Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest ischemic stroke Stories

2014-03-28 08:27:33

First Study To Validate Cell Survival and Functionality in Brain, Improvement Dose Dependent ROCKVILLE, Md., March 28, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem's NSI-566 stem cells in the brain experienced functional improvements. Furthermore, the grafts both survived and differentiated into neurons. These findings further validate the...

2014-03-10 08:31:05

ROCKVILLE, Md., March 10, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trials program and reported its 2013 financial results for the year ended December 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) "2013 was an exciting year for advancement in our NSI-566 cell therapy clinical programs," said Karl Johe, PhD, Neuralstem's Chairman of the Board and Chief Scientific Officer. "Our Phase II ALS trial...

2014-01-13 12:27:02

ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in the Phase I/II NSI-566 stem cell trial to treat motor deficits from ischemic stroke at BaYi Brain Hospital in Beijing, China. The patient received treatment on December 27, 2013 and has now returned home. The trial is sponsored by Neuralstem's wholly-owned subsidiary, Neuralstem China (Suzhou Sun-Now Biopharmaceutical Co. Ltd.), which was formed to develop...

2013-10-01 13:44:03

The oral hormone therapy conjugated equine estrogens (CEEs), which is used by women to relieve menopause symptoms, appears to be associated with increased risk for venous thrombosis (VT, blood clots) and possibly myocardial infarction (heart attack), but not ischemic stroke risk, when compared with the hormone therapy oral estradiol, according to a study published by JAMA Internal Medicine, a JAMA Network publication. Researchers compared the cardiovascular safety of the two commonly used...

2013-09-02 10:16:37

The findings were presented at the ESC Congress today by Ms Stina Jakobsson from Sweden. They reveal that reperfusion therapy and secondary prevention drugs produced the decline and brought stroke risk after AMI closer to that of non-diabetics. Ms Jakobsson said: "Ischemic stroke following an acute myocardial infarction is a fairly uncommon but devastating event with high mortality. It has long been recognized that patients with diabetes mellitus are at a particularly high risk of...

2013-08-01 12:28:40

Clinical Trial to Evaluate Novel Ultrasound Treatment at Over 60 Leading Stroke Centers Worldwide REDMOND, Wash., Aug. 1, 2013 /PRNewswire/ -- Cerevast Therapeutics, Inc., a privately-held medical technology company, announced today that it has initiated patient enrollment in its Phase 3 clinical trial evaluating the use of the Company's proprietary Clotbust ER(TM) ultrasonic headframe for the treatment of acute ischemic stroke. This worldwide study intends to enroll up to 800...

2013-03-14 17:23:00

When someone has a stroke, time equals brain. The longer a stroke is left untreated, the more brain tissue is lost. Since the only proven treatment – a clot-busting drug – works in less than half of patients, stroke physicians had high hopes for a mechanical device that could travel through the blocked blood vessel to retrieve or break up the clot, restoring blood flow to the brain. But in a recently completed multi-site trial in which UCLA served as the clinical coordinating...

2013-03-05 08:30:03

Data Demonstrate Increased Blood Flow and Vasculogenesis in Models of Ischemic Stroke and Peripheral Vascular Disease CAMBRIDGE, Mass., March 5, 2013 /PRNewswire/ -- Tarix Pharmaceuticals, a biopharmaceutical company focused on developing novel, peptide-based therapies to treat a range of critical medical conditions, today announced it has uncovered a new role for its therapeutic peptides in stimulating revascularization following ischemia. In models of ischemic stroke and...

2013-02-21 11:39:12

Research conducted by a team of scientists from Columbia University College of Physicians and Surgeons and Dr. Nicolas Bazan, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, found the novel use of a component of fish oil reduced brain trauma in newborn mice. The study reports that neonatal brain damage decreased by about 50% when a triglyceride lipid emulsion containing docosahexaenoic acid (DHA) was injected within two hours of...

2013-02-11 16:27:19

Clinical trial seeks to enroll people with disabling effects of ischemic stroke CHICAGO, Feb. 11, 2013 /PRNewswire-USNewswire/ -- Each year, nearly 800,000 Americans suffer a stroke which can result in permanent brain damage, long term disability or death. As a leading cause of adult disability, stroke has an annual burden of more than $62 billion on the United States economy. With the exception of rehabilitation therapy, very few treatments are available to improve the chronic...